Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
作者信息
Rodríguez-Villodres Ángel, Ortiz de la Rosa José Manuel, Álvarez-Marín Rocío, Pachón Jerónimo, Aznar Javier, Lepe José Antonio, Smani Younes
机构信息
Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain.
Department of Medicine, University of Seville, Seville, Spain.
出版信息
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01923-17. Print 2018 Jan.
Abstract
摘要
相似文献
1
Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.大肠杆菌序列型131临床分离株对哌拉西林-他唑巴坦的异质性耐药
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01923-17. Print 2018 Jan.
2
Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.β-内酰胺酶和外排泵过度表达对临床分离大肠埃希菌中他唑巴坦-哌拉西林耐药性的贡献。
Int J Antimicrob Agents. 2020 Apr;55(4):105919. doi: 10.1016/j.ijantimicag.2020.105919. Epub 2020 Feb 13.
3
Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.产CTX-M-15的大肠埃希菌对多利培南及他唑巴坦/哌拉西林产生体外耐药性风险的比较
J Infect Chemother. 2015 May;21(5):381-4. doi: 10.1016/j.jiac.2015.01.006. Epub 2015 Jan 23.
4
Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.ceftolozane-tazobactam 对美国退伍军人（2011 年）中产 ESBLs 的大肠埃希菌分离株的活性与共同耐药性以及 ST131（H30 和 H30Rx）状态的关系
PLoS One. 2018 Jul 10;13(7):e0200442. doi: 10.1371/journal.pone.0200442. eCollection 2018.
5
Evaluation of Piperacillin-Tazobactam ETEST for the Detection of OXA-1 Resistance Mechanism among Escherichia coli and Klebsiella pneumoniae.评估哌拉西林-他唑巴坦 ETEST 检测大肠埃希菌和肺炎克雷伯菌中的 OXA-1 耐药机制。
J Clin Microbiol. 2022 Dec 21;60(12):e0143022. doi: 10.1128/jcm.01430-22. Epub 2022 Nov 23.
6
Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.哌拉西林-他唑巴坦与头孢噻肟在小鼠腹膜炎感染模型中对高产TEM-1型大肠杆菌的疗效
Int J Antimicrob Agents. 2022 Apr;59(4):106543. doi: 10.1016/j.ijantimicag.2022.106543. Epub 2022 Feb 6.
7
Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.产超广谱β-内酰胺酶/β-内酰胺酶抑制剂的耐药性（ESRI）是由低水平耐药的大肠埃希菌演变而来。
J Antimicrob Chemother. 2020 Jan 1;75(1):77-85. doi: 10.1093/jac/dkz393.
8
Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1.产 ESBLs 大肠埃希菌中 blaTEM-1 基因广泛的 IS26 相关基因扩增导致对哌拉西林/他唑巴坦的耐药性。
J Antimicrob Chemother. 2019 Nov 1;74(11):3179-3183. doi: 10.1093/jac/dkz349.
9
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.比较产超广谱β-内酰胺酶和不产超广谱β-内酰胺酶大肠埃希菌分离株的接种物效应对阿莫西林克拉维酸和哌拉西林他唑巴坦抗菌活性的影响。
Clin Microbiol Infect. 2010 Feb;16(2):132-6. doi: 10.1111/j.1469-0691.2009.02893.x. Epub 2009 Jul 15.
10
Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.临床分离大肠埃希菌中哌拉西林/他唑巴坦耐药和扩展谱β-内酰胺类/β-内酰胺酶抑制剂耐药的半快速检测。
Microbiol Spectr. 2021 Oct 31;9(2):e0080121. doi: 10.1128/Spectrum.00801-21. Epub 2021 Oct 20.
引用本文的文献
1
Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study.瑞典乌普萨拉患者大肠埃希菌血流感染中异质性耐药表型的患病率、错误分类及临床后果：一项回顾性队列研究
Lancet Microbe. 2025 Apr;6(4):101010. doi: 10.1016/j.lanmic.2024.101010. Epub 2025 Jan 16.
2
Fosfomycin Disk Diffusion Testing among Klebsiella pneumoniae Results in Frequent Inner Colonies and Categorical Disagreement Based on Conflicting Breakpoint Organization Recommendations.肺炎克雷伯菌中磷霉素纸片扩散试验导致频繁出现内部菌落以及基于相互冲突的断点组织建议而产生的分类分歧。
Microbiol Spectr. 2023 Mar 6;11(2):e0336322. doi: 10.1128/spectrum.03363-22.
3
Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant by the MALDIpiptaz test.MALDIpiptaz 试验对 ESRI 开发人员和哌拉西林/他唑巴坦耐药的超灵敏和快速鉴定。
Emerg Microbes Infect. 2022 Dec;11(1):2034-2044. doi: 10.1080/22221751.2022.2113746.
4
Phylogeny, Resistome, and Virulome of Causing Biliary Tract Infections.引起胆道感染的系统发育、耐药基因组和病毒基因组
J Clin Med. 2019 Dec 2;8(12):2118. doi: 10.3390/jcm8122118.
本文引用的文献
1
Epidemiological and clinical features for cefepime heteroresistant Escherichia coli infections in Southwest China.中国西南地区头孢吡肟异质性耐药大肠埃希菌感染的流行病学及临床特征
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):571-8. doi: 10.1007/s10096-015-2572-x. Epub 2016 Jan 27.
2
Impact of carbapenem heteroresistance among clinical isolates of invasive Escherichia coli in Chongqing, southwestern China.中国西南部重庆市侵袭性大肠埃希菌临床分离株中碳青霉烯类异质性耐药的影响。
Clin Microbiol Infect. 2015 May;21(5):469.e1-10. doi: 10.1016/j.cmi.2014.12.013. Epub 2014 Dec 26.
3
Antimicrobial heteroresistance: an emerging field in need of clarity.抗菌异质性耐药：一个亟待明确的新兴领域。
Clin Microbiol Rev. 2015 Jan;28(1):191-207. doi: 10.1128/CMR.00058-14.
4
Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.由泌尿系统感染分离出的哌拉西林/他唑巴坦异质性耐药铜绿假单胞菌，用哌拉西林/他唑巴坦成功治疗。
J Antimicrob Chemother. 2008 Mar;61(3):757-8. doi: 10.1093/jac/dkm528. Epub 2008 Jan 15.
5
Sex and virulence in Escherichia coli: an evolutionary perspective.大肠杆菌中的性别与毒力：进化视角
Mol Microbiol. 2006 Jun;60(5):1136-51. doi: 10.1111/j.1365-2958.2006.05172.x.
6
Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals.从食品、人类和健康动物中分离出的耐氨苄西林大肠杆菌中的β-内酰胺酶
Antimicrob Agents Chemother. 2002 Oct;46(10):3156-63. doi: 10.1128/AAC.46.10.3156-3163.2002.
Zotero 插件